Form 8-K Sarepta Therapeutics, For: Sep 19

Go back to Form 8-K Sarepta Therapeutics, For: Sep 19

Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer

September 20, 2016 1:18 PM EDT

Oppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).

Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate... More